REFERENCES SLIT APPENDIX

1.

Purello-D’Ambrosio F, Gangemi S, Isola S, et al. Sublingual immunotherapy: a double-blind, placebo-controlled trial with Parietaria judaica extract standardized in mass units in patients with rhinoconjunctivitis, asthma, or both. Allergy. 1999;54(9):968–73. [PubMed: 10505460]

2.

Pajno GB, Morabito L, Barberio G, Parmiani S. Clinical and immunologic effects of long-term sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, placebo-controlled study. Allergy. 2000;55(9):842–9. [PubMed: 11003448]

3.

Nelson HS, Oppenheimer J, Vatsia GA, Buchmeier A. A double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized cat extract. J Allergy Clin Immunol. 1993;92(2):229–36. [PubMed: 8349933]

4.

Cortellini G, Spadolini I, Patella V, et al. Sublingual immunotherapy for Alternaria-induced allergic rhinitis: a randomized placebo-controlled trial. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology. 2010:382–6. [PubMed: 21055665]

5.

Stelmach I, Kaczmarek-Wozniak J, Majak P, Olszowiec-Chlebna M, Jerzynska J. Efficacy and safety of high-doses sublingual immunotherapy in ultra-rush scheme in children allergic to grass pollen. Clin Exp Allergy. 2009;39(3):401–8. [PubMed: 19134016]

6.

Penagos M, Passalacqua G, Compalati E, et al. Metaanalysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age. Chest. 2008;133(3):599–609. [PubMed: 17951626]

7.

Lue KH, Lin YH, Sun HL, Lu KH, Hsieh JC, Chou MC. Clinical and immunologic effects of sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, randomized, placebo-controlled study. Pediatr Allergy Immunol. 2006;17(6):408–15. [PubMed: 16925685]

8.

Niu CK, Chen WY, Huang JL, Lue KH, Wang JY. Efficacy of sublingual immunotherapy with high-dose mite extracts in asthma: a multi-center, double-blind, randomized, and placebo-controlled study in Taiwan. Respir Med. 2006;100(8):1374–83. [PubMed: 16403616]

9.

Sambugaro R, Puccinelli P, Burastero SE, Di Rienzo V. The efficacy of sublingual immunotherapy for respiratory allergy is not affected by different dosage regimens in the induction phase. Allergol Immunopathol (Madr). 2003;31(6):329–37. [PubMed: 14670288]

10.

Horiguchi S, Okamoto Y, Yonekura S, et al. A randomized controlled trial of sublingual immunotherapy for Japanese cedar pollinosis. Int Arch Allergy Immunol. 2008;146(1):76–84. [PubMed: 18087165]

11.

Okubo K, Gotoh M, Fujieda S, et al. A randomized double-blind comparative study of sublingual immunotherapy for cedar pollinosis. Allergol Int. 2008;57(3):265–75. [PubMed: 18566549]

12.

Fujimura T, Yonekura S, Horiguchi S, et al. Increase of regulatory T cells and the ratio of specific IgE to total IgE are candidates for response monitoring or prognostic biomarkers in 2-year sublingual immunotherapy (SLIT) for Japanese cedar pollinosis. Clin Immunol. 2011;139(1):65–74. [PubMed: 21300571]

13.

Hordijk GJ, Antvelink JB, Luwema RA. Sublingual immunotherapy with a standardised grass pollen extract; a double-blind placebo-controlled study. Allergol Immunopathol (Madr). 1998;26(5):234–40. [PubMed: 9885731]

14.

Tahamiler R, Saritzali G, Canakcioglu S. Long-term efficacy of sublingual immunotherapy in patients with perennial rhinitis. Laryngoscope. 2007;117(6):965–9. [PubMed: 17545861]

15.

Tseng SH, Fu LS, Nong BR, Weng JD, Shyur SD. Changes in serum specific IgG4 and IgG4/IgE ratio in mite-sensitized Taiwanese children with allergic rhinitis receiving short-term sublingual-swallow immunotherapy: a multicenter, randomized, placebo-controlled trial. Asian Pac J Allergy Immunol. 2008;26(2–3):105–12. [PubMed: 19054928]

16.

de Bot CM, Moed H, Berger MY, et al. Sublingual immunotherapy not effective in house dust mite-allergic children in primary care. Pediatr Allergy Immunol. 2011 [PubMed: 22017365]

17.

D’Ambrosio FP, Ricciardi L, Isola S, et al. Rush sublingual immunotherapy in Parietaria allergic patients. Allergol Immunopathol (Madr). 1996;24(4):146–51. [PubMed: 8939269]

18.

La Rosa M, Ranno C, Andre C, Carat F, Tosca MA, Canonica GW. Double-blind placebo-controlled evaluation of sublingual-swallow immunotherapy with standardized Parietaria judaica extract in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol. 1999;104(2 Pt 1):425–32. [PubMed: 10452766]

19.

Leonardi S, Spicuzza L, La Rosa M. High-dose sublingual immunotherapy in children at 8-year follow-up. Ann Allergy Asthma Immunol. 2009;102(3):259–60. [PubMed: 19354077]

20.

Bowen T, Greenbaum J, Charbonneau Y, et al. Canadian trial of sublingual swallow immunotherapy for ragweed rhinoconjunctivitis. Ann Allergy Asthma Immunol. 2004;93(5):425–30. [PubMed: 15562880]

21.

Skoner D, Gentile D, Bush R, Fasano MB, McLaughlin A, Esch RE. Sublingual immunotherapy in patients with allergic rhinoconjunctivitis caused by ragweed pollen. J Allergy Clin Immunol. 2010;125(3):660–6. 666.e1–666.e4. [PubMed: 20153030]

22.

Di Rienzo V, Pucci S, D’Alo S, et al. Effects of high-dose sublingual immunotherapy on quality of life in patients with cypress-induced rhinitis: A placebo-controlled study. Clinical and Experimental Allergy Reviews. 2006

23.

Makino Y, Noguchi E, Takahashi N, et al. Apolipoprotein A-IV is a candidate target molecule for the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol. 2010 [PubMed: 20810159]

24.

Horak F, Stubner P, Berger UE, Marks B, Toth J, Jager S. Immunotherapy with sublingual birch pollen extract. A short-term double-blind placebo study. J Investig Allergol Clin Immunol. 1998;8(3):165–71. [PubMed: 9684190]

25.

Lima MT, Wilson D, Pitkin L, et al. Grass pollen sublingual immunotherapy for seasonal rhinoconjunctivitis: a randomized controlled trial. Clin Exp Allergy. 2002;32(4):507–14. [PubMed: 11972594]

26.

Novembre E, Galli E, Landi F, et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2004;114(4):851–7. [PubMed: 15480326]

27.

Ott H, Sieber J, Brehler R, et al. Efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment: the ECRIT study. Allergy. 2009;64(9):1394–401. [PubMed: 19764942]

28.

Sieber J, Neis M, Brehler R, et al. Increasing long-term safety of seasonal grass pollen sublingual immunotherapy: The ECRIT study. Expert Opinion on Drug Safety. 2012;11(1):7–13. [PubMed: 21980934]

29.

Panzner P, Petras M, Sykora T, Lesna I. Double-blind, placebo-controlled evaluation of grass pollen specific immunotherapy with oral drops administered sublingually or supralingually. Respir Med. 2008;102(9):1296–304. [PubMed: 18585908]

30.

Roder E, Berger MY, Hop WC, Bernsen RM, de Groot H, Gerth van Wijk R. Sublingual immunotherapy with grass pollen is not effective in symptomatic youngsters in primary care. J Allergy Clin Immunol. 2007;119(4):892–8. [PubMed: 17321581]

31.

Sabbah A, Hassoun S, Le Sellin J, Andre C, Sicard H. A double-blind, placebo-controlled trial by the sublingual route of immunotherapy with a standardized grass pollen extract. Allergy. 1994;49(5):309–13. [PubMed: 8092425]

32.

Voltolini S, Modena P, Minale P, et al. Sublingual immunotherapy in tree pollen allergy. Double-blind, placebo-controlled study with a biologically standardised extract of three pollens (alder, birch and hazel) administered by a rush schedule. Allergol Immunopathol (Madr). 2001;29(4):103–10. [PubMed: 11674922]

33.

Marogna M, Spadolini I, Massolo A, Canonica GW, Passalacqua G. Clinical, functional, and immunologic effects of sublingual immunotherapy in birch pollinosis: a 3-year randomized controlled study. J Allergy Clin Immunol. 2005;115(6):1184–8. [PubMed: 15940132]

34.

Voltolini S, Troise C, Incorvaia C, et al. Effectiveness of high dose sublingual immunotherapy to induce a stepdown of seasonal asthma: a pilot study. Curr Med Res Opin. 2010;26(1):37–40. [PubMed: 19895362]

35.

Marogna M, Colombo F, Spadolini I, et al. Randomized open comparison of montelukast and sublingual immunotherapy as add-on treatment in moderate persistent asthma due to birch pollen. Journal of investigational allergology & clinical immunology : official organ of the International Association of Asthmology (INTERASMA) and Sociedad Latinoamericana de Alergia e Inmunología. 2010:146–52. [PubMed: 20461969]

36.

Amar SM, Harbeck RJ, Sills M, Silveira LJ, O’Brien H, Nelson HS. Response to sublingual immunotherapy with grass pollen extract: monotherapy versus combination in a multiallergen extract. J Allergy Clin Immunol. 2009;124(1):150–156. e1–5. [PubMed: 19523672]

37.

Marogna M, Spadolini I, Massolo A, et al. Long-term comparison of sublingual immunotherapy vs inhaled budesonide in patients with mild persistent asthma due to grass pollen. Ann Allergy Asthma Immunol. 2009;102(1):69–75. [PubMed: 19205289]

38.

Stelmach I, Kaluzinska-Parzyszek I, Jerzynska J, Stelmach P, Stelmach W, Majak P. Comparative effect of pre-coseasonal and continuous grass sublingual immunotherapy in children. Allergy: European Journal of Allergy and Clinical Immunology. 2011 [PubMed: 22142341]

39.

Marogna M, Spadolini I, Massolo A, Canonica GW, Passalacqua G. Randomized controlled open study of sublingual immunotherapy for respiratory allergy in real-life: clinical efficacy and more. Allergy. 2004;59(11):1205–10. [PubMed: 15461603]

40.

Marogna M, Spadolini I, Massolo A, et al. Effects of sublingual immunotherapy for multiple or single allergens in polysensitized patients. Ann Allergy Asthma Immunol. 2007;98(3):274–80. [PubMed: 17378260]

41.

Marogna M, Tomassetti D, Bernasconi A, et al. Preventive effects of sublingual immunotherapy in childhood: an open randomized controlled study. Ann Allergy Asthma Immunol. 2008;101(2):206–11. [PubMed: 18727478]

42.

Moreno-Ancillo A, Moreno C, Ojeda P, et al. Efficacy and quality of life with once-daily sublingual immunotherapy with grasses plus olive pollen extract without updosing. J Investig Allergol Clin Immunol. 2007;17(6):399–405. [PubMed: 18088023]

43.

Hirsch T, Sahn M, Leupold W. Double-blind placebo-controlled study of sublingual immunotherapy with house dust mite extract (D.pt.) in children. Pediatr Allergy Immunol. 1997;8(1):21–7. [PubMed: 9260215]

44.

O’Hehir RE, Gardner LM, de Leon MP, et al. House dust mite sublingual immunotherapy: the role for transforming growth factor-beta and functional regulatory T cells. Am J Respir Crit Care Med. 2009;180(10):936–47. [PubMed: 19696440]

45.

Bush RK, Swenson C, Fahlberg B, et al. House dust mite sublingual immunotherapy: results of a US trial. The Journal of allergy and clinical immunology. 2011:974–81. e1–7. [PubMed: 21333346]

46.

Tari MG, Mancino M, Monti G. Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mite. A double-blind study. Allergol Immunopathol (Madr). 1990;18(5):277–84. [PubMed: 2097894]

47.

Bahceciler NN, Isik U, Barlan IB, Basaran MM. Efficacy of sublingual immunotherapy in children with asthma and rhinitis: a double-blind, placebo-controlled study. Pediatr Pulmonol. 2001;32(1):49–55. [PubMed: 11416876]

48.

Guez S, Vatrinet C, Fadel R, Andre C. House-dust-mite sublingual-swallow immunotherapy (SLIT) in perennial rhinitis: a double-blind, placebo-controlled study. Allergy. 2000;55(4):369–75. [PubMed: 10782522]

49.

Marogna M, Spadolini I, Massolo A, Canonica GW, Passalacqua G. Long-lasting effects of sublingual immunotherapy according to its duration: A 15-year prospective study. Journal of Allergy and Clinical Immunology. 2010;126(5):969–975. [PubMed: 20934206]

50.

Pajno GB, Vita D, Feliciotto R, Neri M, Barberio G. Impact of sublingual immunotherapy on seasonal asthma of allergic children to parietaria pollen treated with inhaled fluticasone propionate. Journal of Allergy, Asthma and Immunolgy. [abstract] [PubMed: 14656349]

51.

Pajno GB, Passalacqua G, Vita D, Caminiti L, Parmiani S, Barberio G. Sublingual immunotherapy abrogates seasonal bronchial hyperresponsiveness in children with Parietaria-induced respiratory allergy: a randomized controlled trial. Allergy. 2004;59(8):883–7. [PubMed: 15230823]

52.

Passalacqua G, Albano M, Riccio A, et al. Clinical and immunologic effects of a rush sublingual immunotherapy to Parietaria species: A double-blind, placebo-controlled trial. J Allergy Clin Immunol. 1999;104(5):964–8. [PubMed: 10550740]

53.

Vervloet D, Birnbaum J, Laurent P, et al. Safety and efficacy of Juniperus ashei sublingual-swallow ultra-rush pollen immunotherapy in cypress rhinoconjunctivitis. A double-blind, placebo-controlled study. Int Arch Allergy Immunol. 2007;142(3):239–46. [PubMed: 17114889]

54.

Vourdas D, Syrigou E, Potamianou P, et al. Double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized olive pollen extract in pediatric patients with allergic rhinoconjunctivitis and mild asthma due to olive pollen sensitization. Allergy. 1998;53(7):662–72. [PubMed: 9700035]

55.

Pajno GB, Caminiti L, Crisafulli G, et al. Direct comparison between continuous and coseasonal regimen for sublingual immunotherapy in children with grass allergy: A randomized controlled study. Pediatric Allergy and Immunology. 2011;22(8):803–807. [PubMed: 21929600]

56.

Feliziani V, Lattuada G, Parmiani S, Dall’Aglio PP. Safety and efficacy of sublingual rush immunotherapy with grass allergen extracts. A double blind study. Allergol Immunopathol (Madr). 1995;23(5):224–30. [PubMed: 8526180]

57.

Pfaar O, Klimek L. Efficacy and safety of specific immunotherapy with a high-dose sublingual grass pollen preparation: a double-blind, placebo-controlled trial. Ann Allergy Asthma Immunol. 2008;100(3):256–63. [PubMed: 18426146]

58.

Pradalier A, Basset D, Claudel A, et al. Sublingual-swallow immunotherapy (SLIT) with a standardized five-grass-pollen extract (drops and sublingual tablets) versus placebo in seasonal rhinitis. Allergy. 1999;54(8):819–28. [PubMed: 10485385]

59.

Valovirta E, Jacobsen L, Ljorring C, Koivikko A, Savolainen J. Clinical efficacy and safety of sublingual immunotherapy with tree pollen extract in children. Allergy. 2006;61(10):1177–83. [PubMed: 16942565]

60.

Savolainen J, Jacobsen L, Valovirta E. Sublingual immunotherapy in children modulates allergen-induced in vitro expression of cytokine mRNA in PBMC. Allergy. 2006;61(10):1184–90. [PubMed: 16942566]

61.

de Blay F, Barnig C, Kanny G, et al. Sublingual-swallow immunotherapy with standardized 3-grass pollen extract: a double-blind, placebo-controlled study. Ann Allergy Asthma Immunol. 2007;99(5):453–61. [PubMed: 18051216]

62.

Pozzan M, Milani M. Efficacy of sublingual specific immunotherapy in patients with respiratory allergy to Alternaria alternata: a randomised, assessor-blinded, patient-reported outcome, controlled 3-year trial. Current medical research and opinion. 2010:2801–6. [PubMed: 21050060]

63.

Alvarez-Cuesta E, Berges-Gimeno P, Gonzalez-Mancebo E, Fernandez-Caldas E, Cuesta-Herranz J, Casanovas M. Sublingual immunotherapy with a standardized cat dander extract: evaluation of efficacy in a double blind placebo controlled study. Allergy. 2007;62(7):810–7. [PubMed: 17573730]

64.

Ippoliti F, De Santis W, Volterrani A, et al. Immunomodulation during sublingual therapy in allergic children. Pediatr Allergy Immunol. 2003;14(3):216–21. [PubMed: 12787302]

65.

Rodriguez F, Boquete M, Ibanez MD, de la Torre-Martinez F, Tabar AI. Once daily sublingual immunotherapy without updosing--A new treatment schedule. Int Arch Allergy Immunol. 2006;140(4):321–6. [PubMed: 16741368]

66.

Stevens WJ, Bridts CH. IgG-containing and IgE-containing circulating immune complexes in patients with asthma and rhinitis. J Allergy Clin Immunol. 1984;73(2):276–82. [PubMed: 6699311]

67.

Yonekura S, Okamoto Y, Sakurai D, et al. Sublingual Immunotherapy with House Dust Extract for House Dust-Mite Allergic Rhinitis in Children. Allergol Int. 2010;59(4):1–20. [PubMed: 20864799]

68.

Troise C, Voltolini S, Canessa A, Pecora S, Negrini AC. Sublingual immunotherapy in Parietaria pollen-induced rhinitis: a double-blind study. J Investig Allergol Clin Immunol. 1995;5(1):25–30. [PubMed: 7551201]

69.

Ring J. [Every tenth person has hay fever complaints. To whom do you advise hyposensitization?]. MMW Fortschr Med. 2004;146(37):12. [PubMed: 15887694]

70.

Tabar AI, Echechipia S, Garcia BE, et al. Double-blind comparative study of cluster and conventional immunotherapy schedules with Dermatophagoides pteronyssinus. J Allergy Clin Immunol. 2005;116(1):109–18. [PubMed: 15990782]

71.

Eifan A, Akkoc T, Yildiz A, et al. Clinical efficacy and immunological mechanisms of sublingual and subcutaneous specific immunotherapy in asthmatic/rhinitis children sensitised to house-dust-mite: an open randomised controlled study. Allergy. 2010 [PubMed: 20100188]

72.

Mauro M, Russello M, Incorvaia C, Gazzola GB, Di Cara G, Frati F. Comparison of efficacy, safety and immunologic effects of subcutaneous and sublingual immunotherapy in birch pollinosis: a randomized study. Eur Ann Allergy Clin Immunol. 2007;39(4):119–22. [PubMed: 17523385]

73.

Mungan D, Misirligil Z, Gurbuz L. Comparison of the efficacy of subcutaneous and sublingual immunotherapy in mite-sensitive patients with rhinitis and asthma--a placebo controlled study. Ann Allergy Asthma Immunol. 1999;82(5):485–90. [PubMed: 10353581]

75.

Quirino T, Iemoli E, Siciliani E, Parmiani S, Milazzo F. Sublingual versus injective immunotherapy in grass pollen allergic patients: a double blind (double dummy) study. Clin Exp Allergy. 1996;26(11):1253–61. [PubMed: 8955574]

76.

Scadding GK, Brostoff J. Low dose sublingual therapy in patients with allergic rhinitis due to house dust mite. Clin Allergy. 1986;16(5):483–91. [PubMed: 3536171]